|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. David Loew||MD, CEO & Director||2,3M||S.O.||1967|
|Mr. Aymeric Le Chatelier||Exec. VP & Group CFO||S.O.||S.O.||1969|
|Dr. Aidan Murphy Ph.D.||Exec. VP of Technical Operations||S.O.||S.O.||1966|
|Mr. Craig Marks||Vice-Pres of Investor Relations||S.O.||S.O.||S.O.|
|Mr. Francois Garnier||Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer||S.O.||S.O.||1962|
|Ms. Gwenan White||Exec. VP of Communications & Public Affairs||S.O.||S.O.||S.O.|
|Mr. Regis Mulot||Exec. VP & Chief HR Officer||S.O.||S.O.||1966|
|Mr. Stephan Gagne||Head of New Tokyo Office||S.O.||S.O.||S.O.|
|Ms. Dominique Bery||Head of Nordics & Baltics||S.O.||S.O.||1971|
|Dr. Yan Moore M.D.||Sr. VP & Head of Oncology Therapeutic Area||S.O.||S.O.||1967|
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
L’ISS Governance QualityScore de Ipsen S.A. en date du 1 février 2023 est 9. Les scores principaux sont Audit : 6; Société : 9; Droits des actionnaires : 7; Compensation : 7.